このエントリーをはてなブックマークに追加
ID 49391
FullText URL
Thumnail 125_77.pdf 223 KB
Title Alternative
Genetic polymorphisms as susceptibility factors for drug response
Author
Kuroda, Satoshi
Note
キーワード (Keyword)
Published Date
2013-04-01
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume125
Issue
issue1
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
77
End Page
78
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, et al. : Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese : roles of UGT1A1*6 and *28. Pharmacogenet Genomics (2007) 17, 497-504.
2) Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L : Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2009) 360, 363-375.
3) SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R : SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med (2008) 359, 789-799.
4) Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, et al. : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361, 947-957.
5) De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, et al. : Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 304, 1812-1820.
6) Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM : Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 358, 999-1008.
7) Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, et al. : Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics (2006) 16, 297-306.
8) Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, et al. : HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia (2010) 51, 2461-2465.
9) Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara T, Hashimoto K, Kamatani N, Nakamura Y : Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet (2011) 20, 1034-1041.
10) Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, et al. : A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J (2013) 13, 60-69.
11) Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, Jee YK : HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics (2010) 11, 879-884.
language
日本語
Copyright Holders
Copyright (c) 2013 岡山医学会
File Version
publisher
Refereed
True
DOI
Eprints Journal Name
joma